PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?

被引：13
|
作者：
Cainzos-Achirica, Miguel [1 ]
Martin, Seth S. [1 ]
Cornell, John E.
Murow, Cynthia D.
Guallar, Eliseo
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2015年 / 163卷 / 01期
关键词：
HYPERCHOLESTEROLEMIA; LDL;
D O I：
10.7326/M15-0920
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [21] Economic Aspects of Lipid-Lowering Therapy Are PCSK9 Inhibitors cost-effective at their current Price?
    Schloegl, Haiko
    DIABETOLOGE, 2019, 15 (03): : 258 - 259
  • [22] Lipids and lipid lowering: current management with statins and PCSK9 inhibitors
    Luescher, Thomas F.
    EUROPEAN HEART JOURNAL, 2018, 39 (14) : 1117 - 1120
  • [23] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
  • [24] PCSK9 inhibitors: A new era in stroke prevention?
    Castilla-Guerra, Luis
    Fernandez-Moreno, M. C.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 37 : E44 - E44
  • [25] Drug-Drug Interaction between Antiplatelet Therapy and Lipid-Lowering Agents (Statins and PCSK9 Inhibitors)
    Schroer, Karsten
    Verheugt, Freek W. A.
    Trenk, Dietmar
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (02) : 166 - 176
  • [26] Lipid-Lowering Therapy and Intracerebral Hemorrhage Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors
    Cuesta, Sanz Borja E.
    Saver, Jeffrey L.
    STROKE, 2021, 52
  • [27] Lipid-Lowering Therapy and Hemorrhagic Stroke Risk Comparative Meta-Analysis of Statins and PCSK9 Inhibitors
    Sanz-Cuesta, Borja E.
    Saver, Jeffrey L.
    STROKE, 2021, 52 (10) : 3142 - 3150
  • [28] Improvement of retinal microvascular function after initiation of lipid-lowering therapy with PCSK9 inhibitors - an observational study
    Naegele, M.
    Raemy, Y.
    Barthelmes, J.
    Kreysing, L.
    Haider, T.
    Ruschitzka, F.
    Flammer, A. J.
    Sudano, I.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3363 - 3363
  • [29] Limitations of cholesterol lowering with PCSK9 inhibitors
    Thompson, Gilbert
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (04): : 241 - 243
  • [30] Lower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid-lowering therapy
    Wojcik, Cezary
    REVIEWS IN HEALTH CARE, 2016, 7 (01) : 17 - 25
12345